Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 733

Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA

Dr Corinne Summers speaks to ecancer at ASH 2018 about the potential role stem cell transplantation plays in long-term outcomes after CD19 CAR T-cell therapy for paediatric patients.

She explains that the follow-up reveals late relapse recurrences and that patients with ALL who received a first stem cell transplant after therapy were less likely to experience a relapse, but the role of second transplant is still unclear.

Dr Summers concludes that more follow-up is needed in phase II, which is now underway.

Watch her press conference here.

Read more about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.  

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation